Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Saroglitazar Magnesium

    Tag: saroglitazarmagnesium

    You Searched For "Saroglitazar Magnesium"
    Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    Medical Dialogues Bureau5 Aug 2019 10:00 AM IST
    Saroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and...
    Patients with NASH have been enrolled in 3 phase III trials of Saroglitazar, says Zydus Cadila

    Patients with NASH have been enrolled in 3 phase III trials of Saroglitazar, says Zydus Cadila

    Medical Dialogues Bureau18 July 2019 9:17 AM IST
    "Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico," Cadila Healthcare, the listed entity of the group,...
    Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH

    Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH

    Medical Dialogues Bureau19 Jun 2019 12:01 PM IST
    AHMEDABAD: Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrolment of 104 patients with...
    Zydus gets regulatory nod to market Lipaglyn in Mexico

    Zydus gets regulatory nod to market Lipaglyn in Mexico

    Ruby Khatun Khatun11 Nov 2017 10:32 AM IST
    New Delhi: Drug firm Zydus said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok